This post was written by Christopher C. Foster. As many of you no doubt have heard, the United States Supreme Court last week decided that FDA regulations applicable to generic drug manufacturers preempt state law “failure to warn” claims in PLIVA, Inc. v. Mensing, Nos. 09โ993, 09โ1039, and 09โ1501, 564 U.S. ___ (2011). Among other … Continue Reading